Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Current Hematologic Malignancy Reports
|
January 11, 2014
Genetic events other than BCR-ABL1
Paolo Neviani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
SETting OP449 into the PP2A-activating drug family
Paolo Neviani, Danilo Perrotti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way
Danilo Perrotti, Paolo Neviani
Frontiers in Medicine
|
August 11, 2015
Exosomic microRNAs in the Tumor Microenvironment
Paolo Neviani, Muller Fabbri
The Lancet. Oncology
|
May 4, 2013
Protein phosphatase 2A: a target for anticancer therapy
Danilo Perrotti, Paolo Neviani
Cancer Metastasis Reviews
|
January 24, 2008
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
Danilo Perrotti, Paolo Neviani
Drug Delivery
|
November 30, 2013
Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent
Amelia Parise, Andrea Milelli, Vincenzo Tumiatti, et al.
Mini Reviews in Medicinal Chemistry
|
November 7, 2014
Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies
Andrea Milelli, Carmela Fimognari, Nicole Ticchi, et al.
Investigative Ophthalmology & Visual Science
|
July 6, 2023
CD63/81 Small Extracellular Vesicles in the Aqueous Humor are Retinoblastoma Associated
Sarah Pike, Chen-Ching Peng, Paolo Neviani, et al.
Organic Letters
|
June 23, 2009
Self-assembled hexadecanitroxide
Paolo Neviani, Elisabetta Mileo, Stefano Masiero, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Current Hematologic Malignancy Reports
|
January 11, 2014
Genetic events other than BCR-ABL1
Paolo Neviani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
SETting OP449 into the PP2A-activating drug family
Paolo Neviani, Danilo Perrotti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way
Danilo Perrotti, Paolo Neviani
Frontiers in Medicine
|
August 11, 2015
Exosomic microRNAs in the Tumor Microenvironment
Paolo Neviani, Muller Fabbri
The Lancet. Oncology
|
May 4, 2013
Protein phosphatase 2A: a target for anticancer therapy
Danilo Perrotti, Paolo Neviani
Cancer Metastasis Reviews
|
January 24, 2008
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
Danilo Perrotti, Paolo Neviani
Drug Delivery
|
November 30, 2013
Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent
Amelia Parise, Andrea Milelli, Vincenzo Tumiatti, et al.
Mini Reviews in Medicinal Chemistry
|
November 7, 2014
Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies
Andrea Milelli, Carmela Fimognari, Nicole Ticchi, et al.
Investigative Ophthalmology & Visual Science
|
July 6, 2023
CD63/81 Small Extracellular Vesicles in the Aqueous Humor are Retinoblastoma Associated
Sarah Pike, Chen-Ching Peng, Paolo Neviani, et al.
Organic Letters
|
June 23, 2009
Self-assembled hexadecanitroxide
Paolo Neviani, Elisabetta Mileo, Stefano Masiero, et al.
Page
of 5